Eli Lilly and Company

LLY · NYSE

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.2%

Institutions85.4%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$65.18B	$45.04B	$34.12B	$28.54B	$28.32B	$24.54B	$22.32B	$24.56B	$22.87B	$21.22B
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$11.05B	$8.42B	$7.08B	$6.63B	$7.31B	$5.48B	$4.72B	$6.43B	$6.07B	$5.65B
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$20.64B	$10.59B	$5.24B	$6.24B	$5.58B	$6.19B	$8.32B	$3.23B	-$204.10M	$2.74B
Net income divided by the number of shares outstanding — profit attributable to each share.	$23.00	$11.00	$5.00	$6.00	$6.15	$6.82	$8.00	$3.00	$0.00	$2.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$22.00	$11.00	$5.00	$6.00	$6.12	$6.79	$8.00	$3.00	$0.00	$2.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$7.27B	$3.27B	$2.82B	$2.07B	$3.82B	$3.66B	$2.34B	$8.00B	$6.54B	$4.58B
Everything the company owns that has value — cash, property, inventory, investments, and more.	$112.48B	$78.71B	$64.01B	$49.49B	$48.81B	$46.63B	$39.29B	$43.91B	$44.98B	$38.81B
All of the company's interest-bearing borrowings, short and long term combined.	$42.50B	$33.64B	$25.23B	$16.24B	$16.88B	$16.60B	$15.32B	$12.77B	$13.65B	$10.31B
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$26.54B	$14.19B	$10.77B	$10.65B	$8.98B	$5.64B	$2.61B	$9.83B	$11.59B	$14.01B

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$16.81B	$8.82B	$4.24B	$7.08B	$7.26B	$6.50B	$4.84B	$5.52B	$5.62B	$4.85B

2025-12-31

2024-12-31

2023-12-31

2022-12-31

2021-12-31

2020-12-31

2019-12-31

2018-12-31

2017-12-31

2016-12-31

Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.

$16.81B

$8.82B

$4.24B

$7.08B

$7.26B

$6.50B

$4.84B

$5.52B

$5.62B

$4.85B

	You	Peer avg
P/E	38.6	51.1
Revenue Growth	+47.7%	+5.0%
ROE	102.3%	21.1%

Eli Lilly and Company

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Related Market Insights

Sun Pharma's $11.75 Billion Acquisition of Organon Marks a Landmark Pharma Deal

Sun Pharma Announces $11.75 Billion Acquisition of Organon in Major Healthcare M&A Deal

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison